SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
CLINICAL TRIALS OF ANTIRETROVIRAL THERAPY: TREATMENT NAIVE AND SWITCH
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
8 of
8
|
DOLUTEGRAVIR VS DARUNAVIR/R-BASED ART IN VERY ADVANCED PATIENTS: 48-WEEK RESULTS (ABSTRACT
412)
Jose M Miro
Hospital Clinic, Barcelona, Spain
D/C/F/TAF VS DTG/ABC/3TC FOR INITIAL TREATMENT IN HIV+ ADULTS: A RANDOMIZED STUDY (ABSTRACT
413)
Daniel Podzamczer
Hospital Universitari de Bellvitge, 08907 Barcelona, Spain
DURABLE EFFICACY OF DTG+3TC IN GEMINI-1&2: YEAR 3 SUBGROUP ANALYSES (ABSTRACT
414)
Chloe Orkin
Queen Mary University of London, London, United Kingdom
4-YEAR OUTCOMES OF B/F/TAF IN TREATMENT-NAIVE ADULTS (ABSTRACT
415)
Kimberly Workowski
Emory University, Atlanta, USA
WEEK 96 ANALYSIS OF VIRAL BLIPS FROM A PHASE 2B TRIAL OF ISLATRAVIR AND DORAVIRINE (ABSTRACT
416)
Chloe Orkin
Queen Mary University of London, London, United Kingdom
SWITCHING TO DTG/3TC FDC IS NONINFERIOR TO TBR FOR 96 WEEKS: TANGO SUBGROUP ANALYSES (ABSTRACT
417)
Paul Benson
Be Well Medical Center, Berkley, MI, USA
MISSING DATA, MISSING DIVERSITY: PARTICIPANT DEMOGRAPHICS IN INDUSTRY STUDIES 2010-20 (ABSTRACT
418)
Michael Jon Dorosh
Treatment Educat10n Network, Denver, CO, USA
W96 EFFICACY OF 4/7 DAYS MAINTENANCE ART STRATEGY: ANRS-170 QUATUOR TRIAL (ABSTRACT
419)
Roland Landman
Bichat-Claude Bernard Hospital, Paris, France
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
8 of
8
|
